caa a22 4500 445331305 CHVBK 20180317142738.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10689-010-9403-0 doi (NATIONALLICENCE)springer-10.1007/s10689-010-9403-0 The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer [Elektronische Daten] [Ning Li, Kang Shao, Zhaoli Chen, Bin Qiu, Zhen Wang, Fengwei Tan, Jiwen Wang, Xiaogang Tan, Baozhong Li, Meihua Xiong, Fang Zhou, Jie He] The purpose of this study is to investigate the impact of positive cancer/lung cancer family history (FH) on clinical features and outcome in non-small cell lung cancer (NSCLC) patients. We analyzed 4,491 NSCLC patients with NSCLC who presented from January 1999-December 2005. Chi-square test and Wilcoxon test were used for univariate comparisons, while Cox Proportional Hazards regression analysis was performed to evaluate the adjusted risk of death. Univariate probability of survival was calculated using Kaplan-Meier estimate and compared using the log-rank test. Of 4,491 patients, 579 patients (12.89%) had positive FH, including 233 patients (5.19%) with FH of lung cancer. Patients with positive lung cancer FH, compared to those with negative FH, were diagnosed at earlier age (57 vs. 60; P<0.001), presented more cases of adenocarcinoma (58.80 vs. 50.69%; P=0.016), and at more advanced stage (Stage IIIB/IV 45.74 vs. 36.79%; P<0.001). These differences were also detected in patients with positive cancer FH. In addition, more females and non-smokers were among patients with positive cancer FH (30.05 vs. 26.15%; P=0.045 and 39.90 vs. 33.82%; P=0.008, respectively). Furthermore, patients with advanced cancer (stage IIIB/IV) who had positive FH had lower response rate to chemotherapy (CR&PR 24.68 vs. 34.42%; P=0.024). Nevertheless, patients with positive lung cancer FH had better prognosis (P=0.015), especially if diagnosed at an early stage (P=0.035), and their adjusted relative risk of death was lower (RR 0.69; 95% CI: 0.51-0.93; P=0.015). Definite epidemiologic and survival differences exist between NSCLC patients with positive or negative FH of cancer. Our results suggest that cancer FH is an important factor of clinical features, and could serve as a prognostic indicator for NSCLC. Springer Science+Business Media B.V., 2010 Chemotherapy nationallicence Family history nationallicence Lung cancer nationallicence Non-small-cell lung cancer nationallicence Stage nationallicence Survival nationallicence FH : Family history nationallicence NSCLC : Non-small-cell lung cancer nationallicence Li Ning Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Shao Kang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Chen Zhaoli Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Qiu Bin Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Wang Zhen Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Tan Fengwei Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Wang Jiwen Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Tan Xiaogang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Li Baozhong Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Xiong Meihua Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Zhou Fang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut He Jie Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut Familial Cancer Springer Netherlands 10/2(2011-06-01), 331-336 1389-9600 10:2<331 2011 10 10689 https://doi.org/10.1007/s10689-010-9403-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-010-9403-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Li Ning Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Shao Kang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Chen Zhaoli Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Qiu Bin Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Wang Zhen Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Tan Fengwei Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Wang Jiwen Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Tan Xiaogang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Li Baozhong Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Xiong Meihua Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- Zhou Fang Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 700 1- He Jie Department of Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, 100021, Beijing, People's Republic of China aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/2(2011-06-01), 331-336 1389-9600 10:2<331 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer